1. Pharmacogenomics

Category Archives: Pharmacogenomics

WS2015 – Martin Dawes: Implementation of Pharmacogenomics into Primary Care in British Columbia – Video

Posted on by


WS2015 - Martin Dawes: Implementation of Pharmacogenomics into Primary Care in British Columbia
Genome BC Winter Symposium 2015 held on January 20, 2015 Session 1: User Partnership Program (UPP) Martin Dawes from UBC Department of Family Practice talks ...

By: Genome BC

Follow this link:
WS2015 - Martin Dawes: Implementation of Pharmacogenomics into Primary Care in British Columbia - Video

What Is The Definition Of Pharmacogenomics Medical School Terminology Dictionary – Video

Posted on by


What Is The Definition Of Pharmacogenomics Medical School Terminology Dictionary
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

See the rest here:
What Is The Definition Of Pharmacogenomics Medical School Terminology Dictionary - Video

Pharmacogenomics: Genomics and Drug Response – Richard Weinshilboum, M.D. – Video

Posted on by


Pharmacogenomics: Genomics and Drug Response - Richard Weinshilboum, M.D.
Dr. Weinshilboum joined the staff of Mayo Clinic in Rochester, Minn., in 1972 after earning his M.D. degree at the University of Kansas School of Medicine. He completed residency training in...

By: Mayo Clinic

Follow this link:
Pharmacogenomics: Genomics and Drug Response - Richard Weinshilboum, M.D. - Video

Pharmacogenomics, the next frontier in medicine …

Posted on by

http://www.naturalnews.com/031287_pharmacogenomics_medicine.html

The U.K. has the same problem with its health care system as North America. Only days before Dr. Roses spoke at a scientific meeting in London, the National Health Service reported that the total cost of drugs had soared by 50 percent in the previous three years, from $2.3 billion a year to an annual cost to the taxpayer of $7.2 billion.

An announcement by GSK the previous week promoted a line up of 20 or more new drugs under development that boasted potential earnings of up to $1 Billion (?600m) a year.

Dr. Roses is an academic geneticist originally from Duke University in North Carolina. In his talk he cited figures on how well different classes of drugs work in real patients. And he probably knew just what he was doing - heralding the "brave new world" of genetic engineering and genomics. When you want to promote a new therapy, you have to prove that the previous one is not doing the job or that the new modality at least improves on existing technology. Roses was doing just that when he talked about drugs for Alzheimer's disease working in less than one third of patients, and cancer chemotherapy being effective in less than one in four. Drugs for migraines, osteoporosis, and arthritis do somewhat better and work in about half the patients. His final analysis was that more than 90 percent of drugs work in only 30 to 50 percent of people. That's way less than the placebo effect!

The reason that drugs work effectively, on average, in less than one half of patients according to Dr. Roses, is because their genetic makeup interferes with the medicine in some unknown way. Some people thought it was a gaffe but others admitted that: "Roses is a smart guy and what he is saying will surprise the public but not his colleagues. He is a pioneer of a new culture within the drugs business based on using genes to test for who can benefit from a particular drug."

Roses is on a mission to promote his field of "pharmacogenomics", which applies human genetics to drug development by "identifying "responders", or people who benefit from the drug, with a simple and cheap genetic test that can be used to eliminate those nonresponders who might benefit from another drug. It may be the trend in medicine but it does fly in the face of an industry that markets drugs to the masses, not a select few.

Are we ready to leap into pharmacogenomics when we haven't even mastered nutrition? The late Dr. David Horrobin, a psychopharmacologist and a pioneer in the field of essential fatty acids, asked the quintessential question in his article, "Why do we not make more medical use of nutritional knowledge? How an inadvertent alliance between reductionist scientists, holistic dietitians and drug-oriented regulators and governments has blocked progress." He was probably frustrated with being misquoted so often over the years, thus he made his point perfectly clear in the unwieldy title of his paper.

Dr. Horrobin, a brilliant researcher, questioned whether there was "Something Rotten at the Core of Science?" in a 2001 issue of Trends in Pharmacological Sciences. Commenting on an analysis of the medical journal peer review system and a U.S. Supreme Court decision which questioned the authority of peer review, Dr. Horrobin concluded that, "Far from filtering out junk science, peer review may be blocking the flow of innovation and corrupting public support of science."

Horrobin and a handful of scientists have complained about the peer review process for decades, to no avail. A crack in the armor began in earnest when two researchers, Rothwell and Martyn, laboriously evaluated reviews of papers submitted to two neuroscience journals. They performed a statistical analysis on the correlations among reviewers' recommendations. They concluded that none of the reviewers seemed to agree on anything! Horrobin lamented that, "The core system by which the scientific community allots prestige (in terms of oral presentations at major meetings and publication in major journals) and funding is a nonvalidated charade whose processes generate results little better than does chance. Given the fact that most reviewers are likely to be mainstream and broadly supportive of the existing organization of the scientific enterprise, it would not be surprising if the likelihood of support for truly innovative research was considerably less than that provided by chance."

Horrobin noted that scientists often become angry because the public rejects the results of the scientific process. However, the Rothwell and Martyn report indicates that the public may be on the right track and is waiting for science to do more than just state its superiority but actually put itself to objective evaluation. Dr. Horrobin found that in the midst of the rejection of science by the public there is also the fact that pharmaceutical research is failing. The annual number of new chemical entities submitted for approval is steadily declining. Horrobin concluded that drug companies are merging because of failure; it is not a measure of success.

In his field of psychopharmacology, Dr. Horrobin said he was able to find no improvement in the treatment of depression and schizophrenia in the past forty years. "Is it really a success that 27 of every 100 patients taking the selective 5HT reuptake inhibitors stop treatment within six weeks compared with the 30 of every 100 who take a 1950's tricyclic antidepressant compound?"

Of course, I say my Future Health Now! online lifestyle and wellness program is the future of medicine, not genetic engineering. William Leiss is past President of the Royal Society of Canada and a widely sought after advisor on the social and ethical implications of "risk controversies and public policy." In an interview available online, Leiss attempts to warn government and the public about galloping technology. Dr. Leiss says there is an unresolved tension between two competing aspects of the scientific revolution in the modern world.

There is a battle between inventive science, the creation of products, and transformative science, which results in cultural change. Inventive science goes from triumph to triumph virtually uncontested and is bolstered by unlimited funding. Even though Francis Bacon in the 1600s championed inventions as a way of improving the human race, it was not until the end of the 1800s that Bacon's dream was realized. The first inventions were in the field of chemistry.

Transformative science was championed in the 1700s as a way of not just understanding and overcoming nature but as an important new way of organizing the basis of social institutions, promoting universal education and rendering social policies and institutes more humane and just.

Dr. Leiss reminds us of the many risks we have overcome through advancement in invention and transformative science. Where would we be if it were not for the many products that have advanced the world through childbirth morality, infant and childhood mortality, infectious diseases, malnutrition, personal security, accidents, birth control, and the treatment of mental disorders reflected in an increase in average lifespan? Bacon would be happy that we have achieved results far beyond what he had expected, however, Leiss is afraid we don't know when to put the brakes on technology. He also asks why have we accepted without challenge most new inventions that have darkened our door?

When it comes to genetic engineering, affecting our very DNA, proponents envision programming perfection in humans, doubling the human lifespan, and developing entirely new life forms once scientists have mastered the necessary genome that will sustain human life.

Leiss thinks that by the late 19th century, the products of science began to be more important than improvement of society through transformative science. He reminds us that World War II brought us extremely close to nuclear war and changed the world immeasurably. But Leiss feels the final frontier is biotechnology that is capable of "modifying" genes at the embryo stage. For neurodegenerative diseases like Huntington's Chorea, this treatment could be a miracle. But what is to stop scientists from enhancing normal performance and creating super geniuses, super athletes, super entertainers, or super politicians. Many questions are yet to be asked. How will these changes affect the gene pool? What about the notion of extending human life? Leiss, with tongue firmly incheek, speculates about a 200year life span and spending the last 100 years of life on cruise ships!

Dr. Epstein, a professor of environmental and occupational medicine at The School of Public Health, University of Chicago, spoke at The Lighthouse in New York on November 11, 2001. He said that this century has seen the emergence of new technologies: petrochemicals developed around 1940 with new methods of fractional distillation creating 1 billion pounds in 1940, 50 billion by 1950 and now an annual production of 900 billion pounds; a second concern is nuclear technology and fuel; a third is genetic engineering, an emerging technology with the potential for irreversible health effects.

Epstein says these technologies outstrip any social mechanism that would try to control them. Therefore, we have a complex set of factors, which add up to seeing the actual abolition and desecration of democratic structure by corporate influences on national and government levels. Most journalists in a kneejerk reaction cheer on the technologies, says Dr. Epstein, and furthermore, they never see a carcinogen they don't like.

Less than six months after Dr. Roses made his startling announcement that 90 percent of drugs only work on 3050 percent of the population, GlaxoSmithKline sponsored a special edition of the wellknown scientific journal, Nature. It was called "Nature: Insight on Human Genomics and Medicine" and GSK defined the parameters of the journal as follows:

1. Pharmacogenetics exploring the genetic basis for drug response to find the right medicine for the right patient.

2. Disease Genetics - studying patient populations with common disease: asthma, depression, COPD, osteoarthritis, early onset heart disease, and migraine in order to identify disease susceptibility genes.

3. Genomics/Proteomics understanding the functions of genes, proteins, and their complex interactions to discover and validate new drug targets and biomarkers.

4. Bioinformatics combining biology, genetics, statistics, and computer.

Exerpted and edited from Death by Modern Medicine: Seeking Safe Solutions, eBook. Dr. Carolyn Dean.

About the author: About the Author: Carolyn Dean MD ND is The Doctor of the Future. She is a medical doctor and naturopathic doctor in the forefront of the natural medicine revolution since 1979. She is working on several patents on novel products including the iCell in RnA Drops. Dr. Dean is a leading expert in magnesium and she has created a picometer, stabilized-ionic form of magnesium, called ReMag that's 100% absorbed at the cellular level and non-laxative making it one of the only magnesiums that can be taken in therapeutic amounts with no side effects. ReLyte is her multiple mineral product that is also completely absorbed at the cellular level and contains the 9 minerals necessary for supporting proper thyroid function. RnA Drops help make perfect cells via RNA through Chromosome 14 affecting DNA. ReNew, which is highly concentrated RnA Drops is a powerful skin serum and ReAline is a safe detox formula with methylated B's, l-taurine and dl-methionine (the precursor to glutathione), all available at http://www.RnAReSet.com Dr. Dean is the author/coauthor of 33 health books (print and eBooks) and 106 Kindle books including The Magnesium Miracle, Death by Modern Medicine, IBS for Dummies, IBS Cookbook for Dummies, The Yeast Connection and Women's Health, Future Health Now Encyclopedia, Death by Modern Medicine, Everything Alzheimers, and Hormone Balance. She is on the Medical Advisory Board of the non-profit educational site - Nutritional Magnesium Association (www.nutritionalmagnesium.org). Dr. Dean has a free online newsletter and a valuable online 2-year wellness program called Completement Now! at http://www.drcarolyndean.com/fhn. She also runs a busy telephone consulting practice and has a weekly radio show Mondays at 4pm PST on http://www.achieveradio.com. Find out more at http://www.drcarolyndean.com, http://www.drcarolyndeanlive.com, http://www.RnAReSet.com, and http://www.howionic.com.

Permalink to this article: http://www.naturalnews.com/031287_pharmacogenomics_medicine.html

Embed article link: (copy HTML code below): Pharmacogenomics, the next frontier in medicine?

Reprinting this article:

Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Go here to see the original:
Pharmacogenomics, the next frontier in medicine ...

Pharmacogenomic Companies – The Authority on …

Posted on by

Weve compiled this list of Pharmacogenomic companies, researchers, and

services to provide our readers with access to information and services they may need. This is by no means a comprehensive list of pharmacogenomic companies and if you feel you have a company or business that you would like us to add to this list please contact us by email or any of the social media links on the website.

Myriad a leading pharmacogenomics company, through pioneering research and the development of innovative molecular diagnostic tests dedicates its resources to the enhancement of personalized medicine. Myriad has devoted over $1 billion to expansion of the international scientific understanding of diseases through research. That research has been formed into molecular data that has proven to save and improve the quality of life fortheir clientele. Myriads research has proven, time and time again, that their data anylisis can identify a persons chances of responding to a certain treatment plan -specifically drug therapy- and tailor their recovery program to ensure an effective treatment and quick recovery time. This data also shows the doctors the likeliehood of developing other disease or health risks in the future. Today and everyday we reaffirm our commitment to serving as both a trusted advisor to patients and healthcare professionals and a collaborator with the scientific community.

Contact Info:

Myriad Genetics, Inc. 320 Wakara Way Salt Lake City, UT 84108 Phone: (801) 584-3600 Fax: (801) 584-3640

Myriad Website

Trans genomic is an international biotech company that specializes in the advancements of personalized medicine in cardiology, oncology, and other diseases through its molecular technology and world renowned laborites. Transgenomic is an international leader in pharmacogenetic testing with a plethora of innovative products developed to detect specific mutations in certain gene structures that are indicative to certain cardiac disorders. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, Transgenomic Pharmacogenomic Services, Transgenomic Diagnostic Tools, Transgenomic believes there is significant opportunity for continued growth in personalized medicine and continues to strive to be the leader in Pharmacogenetic testing.

Contact Info: Transgenomic, Inc. 12325 Emmet Street Omaha, NE 68164, USA Phone: 402-452-5400 / 888-813-7253 Fax: 402-452-5401 E-mail: info@transgenomic.com Transgenomic Website

The new 23andMe is a personalized genetic testing company that provides ancestry-related genetic details. They give raw, uninterpreted genetic data through an in-home, Direct to Consumer saliva test. Once a customer, 23andMe helps educate consumers on their results. This allows them to gain a better understanding of diseases, or hereditary disorders that they, or their children may be susceptible to. They believe that your DNA composition is information that you should know and have tested so that you can prepare for the future. They also believe that it would behove the world if you shared that information so that the scientists of the world could potentially eradicate or overcome some of the worlds new/future diseases.

Contact info

1390 Shorebird Way Mountain View, CA94043 Phone: (650)938-6300 Fax: (650)938-6305 Email: media@23andme.com

A privately-held global precision medicine diagnostic company that has developed megawatt bases that link directly to a mobile application that gives physicians and patients alike the ability to take control of their health and wellness and be proactive in treating diseases realtime. They offer genetic testing that will get uploaded to the data base and cross referenced with the other individuals that participate so that we can get the right solution, right now. They work in direct partnership with physicians and do not do DTC. They own and operate a lab that is accredited by the CAP and CLIA.

Contact info

4755 Nexus Center Dr San Diego, CA 92121 Phone: (858) 450-6600 Fax: (877) 505-7374 Email: clientservices@pathway.com

Founded over 40 years ago by Robert A. Swanson and Herbert Boyer Genetech has been delivering innovations to biotechnology and genetic testing since the beginning. Genetech creates, builds, and markets testing to help patients right now. Genetech strives to offer solutions to patients right now, while developing tests and solutions for the future simultaneously. The goal is to change patients lives through their courageous decision making and action. Each day, employees and Genetech come to work because they, We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow. Genetic has shown through its tenure that is is committed to the betterment of human life and isnt going anywhere.

Contact info

1 DNA Way Mailstop 258A South San Francisco, CA94080 Phone: (888) 835-2555 Fax: (650) 225-4630

GeneDx was founded by two scientists from the National Institutes of Health, Dr. Sherri Bale and Dr. John Compton. Their mission is to make genetic testing readily available to those families that are affected by rare genetic conditions that can cause hereditary disorders. Their testing utilizes DNA sequencing to test for over 200 Mendelian disorders. GeneDx is also an innovator for genetic testing for autism and other chromosomal anomalies. One of the most beneficial tests, is the genetic test GeneDx created for cardiomyopathy. GeneDx does not provide direct to consumer (DTC) testing and all testing must be ordered through a patients primary health care physician.

Contact Info

206 Perry ParkwayGaithersburg, MD 20877 Phone: (888)729-1206 Fax: (201) 421-2010 Email: genedx@genedx.com http://www.dnatesting.com

Read the original here:
Pharmacogenomic Companies - The Authority on ...

What Is Pharmacogenomics? | Compass Lab Services, LLC

Posted on by

Pharmacogenomics karly

The term Pharmacogenomics comes from merging the study of drugs (pharmacology) and the study of how traits are inherited (genetics). Pharmacogenomic testing is intended to predict or explain how a person will respond to medicines based on that persons specific genetic characteristics. Pharmacogenomics links specific gene sequences to how the body acts on a drug: absorption, distribution, metabolism, elimination and to how the body responds to the drug: basically desirable or undesirable.

Pharmacogenomic profiles hold the potential to improve prescribing practices for most, if not all drugs. Pretreatment Pharmacogenomic testing has the potential to predict a patients response to or optimal dosing for a specific drug(s). Also, Pharmacogenomic profiles give valuable information on how to avoid or minimize the incidence of adverse drug reactions (ADRS), a leading cause of morbidity and mortality in the United States. This enables healthcare providers to prescribe drug therapy based on unique genetics, making the experience more personalized to each patient.

Sample collection for Pharmacogenomic testing is easy and non-invasive. A simple collection of the buccal (cheek) cells on two different swabs is all that is necessary. The swabs are then placed in DNA-stabilizing solution and ready to be shipped overnight for testing.

Compass Laboratory Services will run a series of tests to determine the genetic variation of the sample. Those results are then analyzed and interpreted to create a Pharmacogenomic profile which the healthcare provider can use as a foundation for optimum drug therapy. Results are reported in an easy-to-read format that breaks down medications into guidance levels of normal, intermediate and poor metabolizers.

Excerpt from:
What Is Pharmacogenomics? | Compass Lab Services, LLC

Canadian Pharmacogenomics Network for Drug Safety

Posted on by

Welcome to The Canadian Pharmacogenomics Network for Drug Safety (CPNDS)

Adverse drug reactions (also known as ADRs or side effects) are a serious public health problem. Pharmacogenomics is the study of the role of genetics in drug response. Biomarkers of drug response can help predict who is at risk of having an ADR and allow patients and clinicians to make more informed decisions about drug treatment options. This is often referred to as personalized medicine.

CPNDS is helping to solve drug safety problems by developing genetic tests that predict which patients are at risk of serious ADRs. The work of CPNDS is to find drug safety solutions, not just find the genetic basis of ADRs. The research of CPNDS entails collecting patient DNA samples, conducting genetic analyses and comparing the gene profiles of patients who experienced an ADR to those who were on the same medication but did not experience an ADR. Results from these investigations can help develop new treatment approaches for future patients.

CPNDS is a multi-disciplinary team consisting of clinicians, researchers, core support staff and trainees. CPNDS researchers are based at academic health centres across Canada, with 13 paediatric sites and 13 adult sites, all coordinated through the national research hub located at the University of British Columbia in Vancouver, British Columbia. Many international collaborations also exist and are highlighted on this webpage. CPNDS is funded by provincial and federal grants.

See the original post here:
Canadian Pharmacogenomics Network for Drug Safety

2nd International Conference on Genomics & Pharmacogenomics Revelant conferences – Video

Posted on by


2nd International Conference on Genomics Pharmacogenomics Revelant conferences
OMICS Group invites all the participants across the globe to attend the 2nd International Conference and Exhibition on Mechanical Aerospace Engineering dur...

By: omicsgroup incorporation

Read the original post:
2nd International Conference on Genomics & Pharmacogenomics Revelant conferences - Video

2nd International Conference on Genomics & Pharmacogenomics Relavant conference – Video

Posted on by


2nd International Conference on Genomics Pharmacogenomics Relavant conference
2nd International Conference on Genomics Pharmacogenomics is going to be held during September 08-10, 2014 at Double Tree by Hilton Hotel-Brownstone-Univer...

By: omicsgroup incorporation

Visit link:
2nd International Conference on Genomics & Pharmacogenomics Relavant conference - Video


  1. Pharmacogenomics